Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute demyelinating optic neuritis.

Rod Foroozan1, Lawrence M Buono, Peter J Savino

  • 1Neuro-Ophthalmology Service, Wills Eye Hospital, Thomas Jefferson Medical College, 840 Walnut Street, Philadelphia, PA 19107, USA.

Current Opinion in Ophthalmology
|November 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: A Lethal Progressive Neuroinflammation Disguised as MOGAD Revealing a Final Diagnosis of Griscelli Syndrome: Regarding: MOGAD is the Most Common Cause of Isolated Optic Neuritis in Children.

Annals of clinical and translational neurology·2026
Same author

MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children.

Annals of clinical and translational neurology·2026
Same author

Racial and Ethnic Disparities in Severe Ischemic Manifestations and Tocilizumab Use Among Patients With Giant Cell Arteritis: A Nationwide Retrospective Cohort Study Using TriNetX.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2026
Same author

Non-Arteritic Anterior Ischaemic Optic Neuropathy and Its Masquerades: A Comprehensive Diagnostic Review.

Clinical & experimental ophthalmology·2026
Same author

Green vessel signal on multicolor imaging as an early sign of ischemic vasculitis in IRVAN Syndrome: A case report.

American journal of ophthalmology case reports·2026
Same author

Variability in Lumbar Puncture Assessment in Patients With Papilledema From Idiopathic Intracranial Hypertension: A Multi-Institutional Review.

The neurologist·2026
Same journal

Laser vision correction (LASIK, PRK, SMILE) with simultaneous accelerated corneal crosslinking.

Current opinion in ophthalmology·2026
Same journal

Traumatic macular hole: observe, operate, or other options.

Current opinion in ophthalmology·2026
Same journal

The evolving role of artificial intelligence in ophthalmology: basic science, translation, and clinical integration.

Current opinion in ophthalmology·2026
Same journal

Editorial: reducing risk for refractive surgery.

Current opinion in ophthalmology·2026
Same journal

Updates on Refractive Surgery: Benefits, Risks, and Costs of Modern Treatment Options.

Current opinion in ophthalmology·2026
Same journal

Corneal Allogeneic Intrastromal Ring Segments for keratoconus - recent evidence and the move to customized and custom shaped CAIRS.

Current opinion in ophthalmology·2026
See all related articles

Early treatment with interferon beta-1a significantly reduces the risk of developing multiple sclerosis (MS) after a first demyelinating event like optic neuritis. This impacts MS prevention strategies for high-risk patients.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Acute demyelinating optic neuritis is a common initial presentation of multiple sclerosis (MS).
  • Previous studies like the Optic Neuritis Treatment Trial (ONTT) highlighted the role of corticosteroids and MRI findings in predicting MS development.
  • The Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) aimed to further refine early intervention strategies.

Purpose of the Study:

  • To evaluate the efficacy of interferon beta-1a in preventing the conversion to clinically definite multiple sclerosis (CDMS) in patients with a first demyelinating episode and characteristic brain lesions.
  • To establish a new standard of care for managing patients at high risk for MS following optic neuritis.

Main Methods:

  • Randomized controlled trial design comparing interferon beta-1a to placebo.

Related Experiment Videos

  • Participants received initial treatment with intravenous corticosteroids.
  • Inclusion criteria required a first clinical episode of demyelination and at least two characteristic brain lesions on MRI.

    • Main Results:

    • Patients treated with interferon beta-1a demonstrated a 50% reduced risk of developing CDMS at the 3-year follow-up.
    • The study established interferon beta-1a as a key therapeutic option for early MS prevention.

    Conclusions:

    • Early treatment with interferon beta-1a is effective in delaying or preventing the conversion to clinically definite multiple sclerosis in high-risk individuals.
    • The CHAMPS study has significantly influenced the management guidelines for patients experiencing their first demyelinating event.